Biomarker Panel for Early Heart Failure Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for heart failure, such as echocardiography and Doppler sonography, are inadequate for detecting presymptomatic stages, leading to poor diagnostic capabilities and low survival rates, as they only diagnose symptomatic heart failure later in the progression.
Innovation Solution
A method involving the measurement of cardiac troponin concentrations, optionally with markers like GDF-15 and IGFBP7, to predict and diagnose early stages of heart failure and structural abnormalities before left ventricular hypertrophy becomes apparent, allowing for early intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (echocardiography and Doppler sonography) are used, then structural and functional abnormalities can be detected, but only in symptomatic later stages of heart failure
Solution Approach 1:
The patent applies preliminary action by detecting biomarkers (cardiac troponin, GDF-15, IGFBP7) in blood samples before the development of symptomatic heart failure. This allows identification of early functional and structural abnormalities preceding left ventricular hypertrophy, enabling intervention before severe damage occurs. The biomarker detection occurs in the presymptomatic stage, thereby preventing progression to later stages requiring traditional diagnostic methods.
2Reliability
If traditional diagnostic methods are used, then heart failure can be diagnosed, but survival rate remains low (50% at 5 years) due to late detection
Solution Approach 1:
By detecting heart failure risk through biomarker analysis in the presymptomatic stage, the patent enables early intervention that improves survival outcomes. The early detection of functional and structural abnormalities allows for timely treatment initiation, which is critical for improving the 5-year survival rate from 50% to higher levels by preventing progression to end-stage heart failure.
Solution Approach 2:
The patent employs feedback mechanisms through continuous monitoring of biomarker levels (cardiac troponin, GDF-15, IGFBP7) to assess heart failure risk and track progression. This feedback loop allows for dynamic adjustment of treatment strategies based on biomarker changes, improving patient outcomes and survival rates by enabling personalized, timely interventions.
3Measurement precision
If biomarker measurement is used to detect early stages, then presymptomatic heart failure can be identified, but the method requires measurement of multiple markers (cardiac troponin, GDF-15, IGFBP7)
Solution Approach 1:
The patent merges multiple biomarkers (cardiac troponin, GDF-15, IGFBP7) into a comprehensive diagnostic panel that works synergistically to detect early heart failure stages. By combining these markers, the system achieves higher sensitivity and specificity for presymptomatic detection compared to any single marker alone, while the markers can be measured using established laboratory techniques.
Solution Approach 2:
The biomarker panel serves multiple functions: cardiac troponin detects myocardial injury, GDF-15 indicates heart failure risk and progression, and IGFBP7 identifies early structural abnormalities. This multi-functional approach allows a single diagnostic system to assess multiple aspects of heart failure risk simultaneously, improving early detection accuracy without requiring separate specialized tests for each marker.
Data Source
AI summary
Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.